ClinicalTrials.gg
CompletedNCT03413384Updated Jul 22, 2026

To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia

A Phase 2 interventional study of Ceftriaxone and Placebo in Parkinson's Disease Dementia, sponsored by BrainX Corporation. Completed at 6 sites in Taiwan. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by BrainX Corporation · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 121 studies in Parkinson Disease with a site in Taiwan — 33 open to participants now, 37 under way, 1 of them phase 3. Parkinson Disease · Taiwan.

Enrollment
19th of 99
100 · median 55
Started
2019
with 7 others
Phase 2
13 of 121
2 open now
Registered
49th of 121
by date

Among the 121 studies in Parkinson Disease with a site in Taiwan, this one is the 19th largest by enrollment of the 99 interventional ones that give a count, is one of 8 that started in 2019, is one of 13 in phase 2, and was the 49th registered.

Parkinson Disease

4,580 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

33 of the 121 studies in Parkinson Disease with a site in Taiwan are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies in Parkinson Disease with a site in Taiwan, or all of them as a file.
02

Study summary

This is a randomized, double blinded, placebo-controlled Phase II study to investigate the efficacy and safety of ceftriaxone in patients with mild to moderate Parkinson's disease dementia (PDD).This study will enroll approximately 106 patients to have up to 84 evaluable subjects, and conduct in Chung Shan Medical University Hospital, National Taiwan University Hospital, Kaohsiung Chang Gung Memorial Hospital, China Medical University Hospital, Changhua Christian Hospital, and Taipei Veterans General Hospital.

Read the detailed description

Parkinson's disease (PD) is a common neurodegenerative disorder that can cause significant disability and decrease quality of life. It is a chronic and progressive disease which means the symptoms become worse over time.

Parkinson's disease dementia (PDD) is a decline in thinking and reasoning that develops in many people living with PD at least a year after diagnosis. An estimated 50 to 80 percent of patients with PD eventually experience dementia as the disease progresses. Ceftriaxone is a kind of antibiotics, which has been marketed in many countries. This is the first time for ceftraxone treatment on PDD patient. The primary objective of this Phase II study is to evaluate the improvement of cognitive function in PDD patients with ceftriaxone administration.

This study will enroll approximately 106 patients, and conduct in multiple hospitals in Taiwan. Recruitment number of each site will be adjusted according to its enrollment status under the competitive enrollment model. Subjects will receive either ceftriaxone or placebo in a 1:1 ratio. One of the subjects' main caregiver should be involved to get the information of function of daily life and help to complete scale evaluation.

The study lasts about 33 weeks, during which eligible patients will be given 1 g/day/dose of ceftriaxone or placebo via injection 3 doses every cycle (2 weekly cycle), for a total of 16 cycles. And the subjects can choose to get injection either in the clinical site or in their house.

03

Conditions studied

  • Parkinson's Disease Dementia

Browse trials for

Keywords

  • Parkinson's Disease
  • Parkinson's Disease Dementia
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients are male or female, age 50-85 years, inclusive.
  2. Diagnosis of idiopathic Parkinson's disease (PD) based on the UK Parkinson's Disease Society Brain Bank Criteria and with a modified Hoehn and Yahr Stage of I to IV.
  3. Patients have been receiving stable dose of medications equivalent up to 1800 mg/day of levodopa for Parkinson's disease at least 2 weeks prior to screening and patients are considered as being optimally treated at screening and no known further adjustments of current medication needed to improve the subject's status of PD during the study period by the judgment of the Investigator based on the subject's history, previous treatments, and the clinical presentation.
  4. Diagnosis of PDD based on Movement Disorder Society (MDS) Task Force criteria as the following items:

    1. A diagnosis of PD based on UK Parkinson's Disease Society Brain Bank Criteria
    2. PD development prior to the onset of dementia based on patient/caregiver history or records
    3. Cognitive deficiency severe enough to impair daily life based on patient/caregiver interview or questionnaire
    4. Impairment of at least 2 of the following domains: attention, executive function, visuo-constructive ability, memory Besides, patients' (MMSE) should be in the range of 18-25 (inclusive) or CDR scale in the range of 0.5-2. Note that MMSE range 16-25 for illiterate. Illiterate is defined as no education history.
  5. Patients who are eligible and able to participate in the study must be judged by the investigator to evaluate the competency of providing for this dementia related study (the decision making is based on MacArthur Competence Assessment concept) and should be able to understand the language in which the tests require so and must be able to perform all the assessments.
  6. All male and female patients with (between puberty and 2 years after menopause) should use at least any one of the appropriate methods shown below, for during and at least 4 weeks after ceftriaxone treatment.

    1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception).
    2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
    3. Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject
    4. Combination of any two of the following listed methods: (d.1+d.2 or d.1+d.3, or d.2+d.3):

    d.1 Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception.

    d.2 Placement of an intrauterine device (IUD) or intrauterine system (IUS). d.3 Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.

Exclusion criteria

Exclusion Criteria:

  1. Any indication of forms of Parkinsonism other than idiopathic PD.
  2. Diagnosis of possible PDD.
  3. Diagnosis of dementia with Lewy Bodies.
  4. Mental/physical/social condition which could preclude performing efficacy or safety assessments.
  5. Medical history of brain or other neurological/psychiatric disorders or injuries other than PD or PDD that would hinder or interfere the study safety or efficacy evaluation in the opinion of the Investigator.
  6. The patients have received neurosurgical intervention related to PD (e.g. deep brain stimulation (DBS), thalamotomy etc.) or are scheduled to do so during the trial period.
  7. The patients have history of allergic response to levodopa, ceftriaxone, cephalosporin class of drugs or ursodiol or lidocaine.
  8. Malignant neoplastic disease, either currently active or in remission for less than 1 year.
  9. Clinically significant and unstable gastrointestinal, renal, endocrine, pulmonary, or cardiovascular disease, including not well controlled hypertension, asthma, , diabetes, hyperbilirubinemia, impaired vitamin K synthesis or low vitamin K stores that would hinder or interfere participation to the study in the opinion of the Investigator.
  10. Patients with abdominal ultrasound examination imaging shows active biliary obstruction disease at PI's discretion during screening.
  11. The patients are currently experiencing unpredictable or intractable or troublesome dyskinesia or fluctuations in their symptoms.
  12. Patients with the following medications that could put patients at risk, interfere with study evaluations, or prevent meeting the requirements of the study at the judgement of PI should be excluded :

    1. Centrally acting anticholinergic medication currently or within 4 weeks prior to the screening visit.
    2. Cocaine, opioids, ethanol (binge drinking or heavy alcohol defined by SAMHSA and NIAAA) currently or within 4 weeks prior to the screening visit; amphetamines, cannabinoids abuse history or taking currently or within 3 months prior to the screening visit.
    3. Acetylcholinesterase inhibitors or memantine currently or within 4 weeks prior to the screening visit, except that patients have been stable controlled and have been receiving stable dose of the acetylcholinesterase inhibitors or memantine for at least 4 weeks prior to screening or are considered being optimally treated at screening without further dose adjustments needed as judged by the Investigator.
    4. Ceftriaxone or cephalosporin or penicillin or β-lactam currently or within 4 weeks prior to the screening visit.
    5. Neuroleptics or antipsychotics for treatment of psychotic symptoms (e.g., hallucinations) within 4 weeks prior to the screening visit, except that patients have been stable controlled and have been receiving stable dose of the neuroleptics or antipsychotics for at least 4 weeks prior to screening or are considered being optimally treated at screening without further dose adjustments needed as judged by the Investigator.
    6. A drug that has severe hepatotoxic or renal toxic within 4 weeks prior to the screening visit.
    7. Warfarin, cyclosporin, vancomycin, amsacrine, aminoglycosides, fluconazole, chloramphenicol currently or within 4 weeks prior to the screening visit.
  13. Currently participating in another clinical trial or who participated in a previous clinical trial and received any product treatment within 4 weeks prior to the screening visit.
  14. Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer from such.
  15. Patients who are not able to take MRI and TRODAT SPECT examination.
  16. Patients who are pregnant or breast feeding.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Ceftriaxone

    1. Name: Ceftriaxone 2. Dosage form: crystalline powder for intramuscular injection 3. Dose(s): 1 g 4. Dosing schedule: 1 g ceftriaxone with around 2.0 ml of lidocaine solvent per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle

    Drug: Ceftriaxone

  • Placebo comparator
    Placebo

    same amount volume of placebo will be given on Day 1, Day 3, and Day 5 per cycle on a 2 weekly cycle

    Other: Placebo

Interventions

  • 1 g ceftriaxone per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle

    Also known as: Ceftriaxone Sandoz powder for IV Injection

  • OtherPlacebo

    Placebo per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle

06

What researchers measure

Primary outcomes

  1. Compare the treatment difference in mean net change in ADAS-Cog score with time course

    ADAS-Cog is a validated instrument to assess dementia covering memory, orientation, language, praxis and consisting of 11 items. The total possible scores range from 70 (severe impairment) to 0 (no impairment).

    Time frame: from baseline to week 17 and 33 visits

Secondary outcomes

  1. Changes in Unified Parkinson's Disease Rating Scale (UPDRS) score

    The UPDRS system is a composite scale intended for rating patients with PD. Scores are rated as 0-4 (0-1 for some Part IV), representing 0=normal and 1 or 4=maximal deficit, symptoms, or impairment.

    Time frame: from baseline to week 17 and 33 visits

  2. Changes in Judgment of Line Orientation score

    The Judgment of Line Orientation (JLO) test is a widely used measure of visuospatial judgment. A score of 17 or less is considered a sign of severe deficit.

    Time frame: from baseline to week 17 and 33 visits

  3. Changes in Mini-Mental State Examination (MMSE) score

    The MMSE is a brief, quantitative measure of cognitive status in adults. The instrument examines orientation, registration, attention, calculation, recall, visuo-spatial abilities and language. The maximum score is 30, with higher scores indicating better cognitive function.

    Time frame: from baseline at week 17 and 33 visits

  4. Changes in Clinical Dementia Rating (CDR) Scale score

    The CDR Scale is a 5-point scale used to characterize 6 domains of cognitive and functional performance applicable to related dementias: memory, orientation, judgment \& problem solving, community affairs, home \& hobbies, and personal care. This score is useful for characterizing and tracking a patient's level of impairment/dementia with 0=normal, 0.5 =very mild dementia, 1=mild dementia, 2=moderate dementia, 3=severe dementia.

    Time frame: from baseline to week 17 and 33 visits

  5. Changes in Color Trail Test score

    Color Trail Test provides quantitative and qualitative information by two trials. The length of time to complete each trial is recorded, along with qualitative features of performance indicative of brain dysfunction, such as near-misses, prompts, number sequence errors, and color sequence errors.

    Time frame: from baseline to week 17 and 33 visits

  6. Changes in MRI image for atrophy rate of brain

    Multimodal MRI examinations will be performed on a 3T MRI scanner with a standard 8-channel head coil. Region of interest in the brain will be evaluated for functional changes including atrophy rate from baseline data.

    Time frame: from baseline to week 17 and 33 visits

  7. Changes in MRI image for dopaminergic projection from substantia nigra to striatum

    Multimodal MRI examinations will be performed on a 3T MRI scanner with a standard 8-channel head coil. Region of interest in the brain will be evaluated for functional changes including dopaminergic projection from baseline data.

    Time frame: from baseline to week 17 and 33 visits

  8. Changes in Tc-99m TRODAT SPECT image

    SPECT assessment will use Tc-99m, a radio tracer with high selectivity and specificity for the striatum dopamine transporter (DAT) density evaluation. DAT density change from baseline will be calculated from region of interest drawn in the striatum by independent readers.

    Time frame: from baseline to week 17 and 33 visits

Other outcomes

  1. Net change of biomarker α-synuclein data

    Patients' plasma samples will be collected to analyze α-synuclen by immunomagnetic reduction (IMR) assay kit developed by Magqu Company.

    Time frame: from baseline to week 17 and 33 visits

  2. Net change of biomarker Aβ42 data

    Patients' plasma samples will be collected to analyze α-synuclen by immunomagnetic reduction (IMR) assay kit developed by Magqu Company.

    Time frame: from baseline to week 17 and 33 visits

07

Study locations

6 sites
  • Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung City, Kaohsiung 83301, Taiwan
  • Chung Shan Medical University Hospital
    Taichung, Taichung 402, Taiwan
  • China Medical University Hospital
    Taichung, Taichung 404, Taiwan
  • National Taiwan University Hospital
    Taipei, Taipei 100, Taiwan
  • Taipei Veterans General Hospital
    Taipei, Taipei 11217, Taiwan
  • Changhua Christian Hospital
    Changhua, 500, Taiwan
08

References and documents

Publications

  • Poewe W, Gauthier S, Aarsland D, Leverenz JB, Barone P, Weintraub D, Tolosa E, Dubois B. Diagnosis and management of Parkinson's disease dementia. Int J Clin Pract. 2008 Oct;62(10):1581-7. doi: 10.1111/j.1742-1241.2008.01869.x. PubMed 18822028 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Jul 2025, 77 months.

Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 77 months is above that.

Counting every sponsor, half of 202 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2018
First posted
Jan 29, 2018
StartActual
Feb 15, 2019
Primary completionActual
Jul 28, 2025
CompletionActual
Mar 13, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03413384
Lead sponsor
BrainX Corporation
Collaborators
Virginia Contract Research Organization Co., Ltd.
Responsible party
Sponsor
First posted
Jan 29, 2018
Start date
Feb 15, 2019
Primary completion
Jul 28, 2025
Completion
Mar 13, 2026
Last update
Jul 22, 2026

Study contacts

Joshua Ho
study director · China Medical University, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ceftriaxone

Start the discussion